1,000
Participants
Start Date
February 27, 2012
Primary Completion Date
February 27, 2017
Study Completion Date
February 27, 2017
"Kallunk oxide (Immunotherapy) "
"The study is assigned Arm 1 above 450 cu/mm\^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
Project Site Office, Hospital of Integrated Research Site HIRS(New), Ahammed Nagar, Mathura Nagar, Bhingar- PO, Mumbai
Project Site Office, Near Sivan Kovil, Nallepily, Hospital of Integrated Research Site HIRS [new]), Palakkad
Project Site Office, Hospital of Integrated Research Site HIRS(New), Karoor, Ambalapuzha-PO, Alleppey-District, Kerala, India 688561, Alappuzha
Traditional Alternative Medicine Research, India
OTHER